home / stock / tltff / tltff news

TLTFF News and Press, Theralase Technologies Inc. From 06/30/23

Stock Information
Company Name: Theralase Technologies Inc.
Stock Symbol: TLTFF
Market: OTC
Website: theralase.com
Menu
TLTFF TLTFF Quote TLTFF Short TLTFF News TLTFF Articles TLTFF Message Board
Get TLTFF Alerts

News, Short Squeeze, Breakout and More Instantly...
TLTFF - Theralase(R) Closes Non-Brokered Private Placement Equity Financing

TORONTO, ON / ACCESSWIRE / June 30, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT ) ( OTCQB:TLTFF ), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (" PDCs ") and their as...
TLTFF - Theralase Technologies shares positive interim results from Phase II Bladder Cancer study

(NewsDirect) Theralase Technologies CEO Roger DuMoulin-White joined Steve Darling from Proactive to share interim data from a Phase II clinical study designed to treat patients diagnosed with Bacillus Calmette-Guérin Unresponsive, Non-Muscle Invasive Bladder Cancer and Carcinoma In-S...

TLTFF - Theralase(R) Announces Appointment of New Independent Director

TORONTO, ON / ACCESSWIRE / June 6, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company focused on the research and development of light-activated Photo Dynamic Compounds (" PDCs ") and their associ...

TLTFF - Theralase(R) Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements

In the Performance to Primary, Secondary and Tertiary Objectives second table the 90 day results were misstated and has been corrected in this press release. TORONTO, ON / ACCESSWIRE / May 30, 2023 / Theralase® Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT )( OTCQB:TLT...
TLTFF - Theralase(R) Releases 1Q2023 Interim Financial Statements

TORONTO, ON / ACCESSWIRE / May 30 2023 / Theralase® Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (" PDCs ") and their associate...

TLTFF - Theralase(R) Appoints Roger DuMoulin-White as President and Chief Executive Officer

TORONTO, ON / ACCESSWIRE / May 24, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT ) ( OTCQB:TLTFF ), a clinical stage pharmaceutical company focused on the research and development of light-activated Photo Dynamic Compounds (" PDCs ") and their assoc...

TLTFF - Theralase Provides Update on Phase II Bladder Cancer Study

For the primary objective, 65% of Evaluable Patients (Patients evaluated by a Principal Investigator ("PI")) achieved a Complete Response ("CR") at any assessment date post primary Study Treatment and 30% of Evaluable Patients achieved a CR at 450 days. TORONTO, ON / ACCESSWIRE / May 10, 2023...
TLTFF - Theralase® Releases FY2022 Audited Financial Statements

TORONTO, April 26, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“ Theralase ” or the “ Company ”) ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo D...

TLTFF - Theralase® Phase II NMIBC Clinical Study (Interim) Data Presented at the ASCO GU Cancer Symposium

TORONTO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Theralase ® Technologies Inc. (“ Theralase ® ” or the “ Company ”) ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company focused on the research and development of light acti...

TLTFF - Theralase® Awarded TSX Venture 50(TM) Recognition as a Top Performing Company

TORONTO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Theralase ® Technologies Inc. (“ Theralase ® ” or the “ Company ”) ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company focused on the research and development of light ...
Previous 10 Next 10